Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells.

Pieper M, Scheffold C, Duwe S, Rossig C, Bisping G, Stelljes M, Tedder TF, Jurgens H, Berdel WE, Kienast J.

Leukemia. 2006 Apr;20(4):729-32. No abstract available.

PMID:
16437143
2.

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.

Jensen MC, Cooper LJ, Wu AM, Forman SJ, Raubitschek A.

Cytotherapy. 2003;5(2):131-8.

PMID:
12745575
3.

CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.

Palomba ML, Roberts WK, Dao T, Manukian G, Guevara-Patiño JA, Wolchok JD, Scheinberg DA, Houghton AN.

Clin Cancer Res. 2005 Jan 1;11(1):370-9.

4.

Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.

Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.

Cancer Res. 2002 Oct 15;62(20):5785-91.

5.

Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.

Chu Y, Hochberg J, Yahr A, Ayello J, van de Ven C, Barth M, Czuczman M, Cairo MS.

Cancer Immunol Res. 2015 Apr;3(4):333-44. doi: 10.1158/2326-6066.CIR-14-0114. Epub 2014 Dec 9.

6.

Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.

Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE.

J Immunother. 2009 Apr;32(3):207-18. doi: 10.1097/CJI.0b013e318194a921.

PMID:
19242379
7.

B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.

Kim S, Fridlender ZG, Dunn R, Kehry MR, Kapoor V, Blouin A, Kaiser LR, Albelda SM.

J Immunother. 2008 Jun;31(5):446-57. doi: 10.1097/CJI.0b013e31816d1d6a.

PMID:
18463540
9.

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.

Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, Beurskens FJ, Parren PW, Winkel JG, Valerius T, Humpe A, Repp R, Gramatzki M, Nimmerjahn F, Peipp M.

Leukemia. 2013 Jan;27(1):190-201. doi: 10.1038/leu.2012.150. Epub 2012 Jun 4.

PMID:
22660187
10.

[An efficient methods for the induction of human antitumor effector CD4+ and CD8+ T cells: their application to tumor immunotherapy].

Nishimura T, Kuge S, Watanabe K, Lee U, Yahata T, Habu S.

Hum Cell. 1994 Sep;7(3):131-7. Review. Japanese.

PMID:
7873496
11.

An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.

Chung Y, Qin H, Kang CY, Kim S, Kwak LW, Dong C.

Blood. 2007 Sep 15;110(6):2013-9. Epub 2007 Jun 20.

12.

Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens.

Dao T, Gomez-Nunez M, Antczak C, Kappel B, Jaggi JS, Korontsvit T, Zakhaleva V, Scheinberg DA.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8763-72.

13.

Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells.

Tita-Nwa F, Moldenhauer G, Herbst M, Kleist C, Ho AD, Kornacker M.

Cancer Immunol Immunother. 2007 Dec;56(12):1911-20. Epub 2007 May 9.

PMID:
17487487
14.

IL-15: targeting CD8+ T cells for immunotherapy.

Diab A, Cohen AD, Alpdogan O, Perales MA.

Cytotherapy. 2005;7(1):23-35. Review.

PMID:
16040381
15.

Antibodies in the treatment of lymphoma.

Leonard JP.

Clin Adv Hematol Oncol. 2004 Apr;2(4):210-1. No abstract available.

PMID:
16163182
17.

B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.

Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.

Exp Hematol. 2010 Mar;38(3):213-21. doi: 10.1016/j.exphem.2009.12.007. Epub 2010 Jan 6.

PMID:
20056126
19.

Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy.

Weiss L, Reich S, Mandelboim O, Slavin S.

Bone Marrow Transplant. 2004 Jun;33(11):1137-41.

PMID:
15077128
20.

Immunotherapy of hematological malignancies using dendritic cells.

Van de Velde AL, Berneman ZN, Van Tendeloo VF.

Bull Cancer. 2008 Mar;95(3):320-6. doi: 10.1684/bdc.2008.0602. Review.

Supplemental Content

Support Center